FDA expands Dupixent indication, EU application to follow

Sanofi and Regeneron’s eczema treatment Dupixent is now approved for use in babies as young as six months old in the US.
Photo: Rodrigo Cid
Photo: Rodrigo Cid
by mikkel aabenhus hemmingsen, translated by catherine brett

Eczema treatment Dupixent can now be used by an even wider group of patients in the US, as the FDA has approved an application to extend the use of the drug.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading